戻る Agenda
[S22] Enabling More Efficient Clinical Studies through TransCelerate Solutions
Session Chair(s)
Makiko Okamoto
Sr. Manager, Clinical Innovations & Business Integration, Medical Development
Eli Lilly Japan K.K., Japan
TransCelerate was founded with a mission to collaborate across biopharmaceutical and R&D communities to identify and help implement solutions to drive the delivery of new medicines. Since its inception, TransCelerate’s membership of 20 leading biopharmaceutical companies has believed that there is significant opportunity to improve the speed, quality and efficiency for all stakeholders in the industry by introducing consistent digital solutions throughout a patient’s clinical trial journey. This session will give a general overview and update on activites across TransCelerate, the tools currently being implemented in Japan, and a roadmap of TransCelerate initiatives and their statuses.
Speaker(s)
TransCelerate Activities General Update
Toshihiro Sano, RPh
Merck Sharp & Dohme LLC , United States
Associate Vice President, Head of Clinical Operations
Initiative Update: SIP (Shared Investigator Platform)
Masahide Matsushima, MSc
Pfizer R&D Japan , Japan
Japan Clinical Project Manager,Clinical Operations
Enabling More Efficient Clinical Studies through TransCelerate Solutions: The CPT and Clinical Content Re-Use
Sian Ratcliffe, PhD
Pfizer Inc, United States
Vice President, Head of Medical Writing
Overview of TransCelerate’s Pharmacovigilance Portfolio
Kouji Kawamura, MSc
Astellas Pharma Inc., Japan
Vice President, Pharmacovigilance JP